Several PARP inhibitors are currently approved by regulatory agencies and used in clinical practice. These include: - Olaparib - Rucaparib - Niraparib - Talazoparib Each of these drugs has been shown to be effective in targeting cancers with specific genetic mutations, particularly those involving BRCA1 and BRCA2.
